Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced BRAF-mutant Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Testing effectiveness (Phase 2)Study completedNCT01902173
What this trial is testing

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmLocally Advanced Malignant Solid NeoplasmLocally Advanced Melanoma+6 more
National Cancer Institute (NCI) 27
Early research (Phase 1)Study completedNCT03415126
What this trial is testing

ASN007 in Patients With Advanced Solid Tumors

Who this might be right for
CancerMalignancyNeoplasia+16 more
Asana BioSciences 49
Early research (Phase 1)Ended earlyNCT06194877
What this trial is testing

Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Who this might be right for
Colorectal CancerPancreatic Ductal CancerAdvanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
MapKure, LLC 13
Testing effectiveness (Phase 2)UnknownNCT04653480
What this trial is testing

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Who this might be right for
Colorectal Cancer
Zhejiang University 61
Testing effectiveness (Phase 2)Ended earlyNCT01777776
What this trial is testing

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Who this might be right for
Locally Advanced Metastatic BRAF Mutant Melanoma
Array BioPharma 28
Testing effectiveness (Phase 2)Ended earlyNCT01616199
What this trial is testing

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Who this might be right for
Advanced BRAF-mutant Cancers
Cascadian Therapeutics Inc. 24
Testing effectiveness (Phase 2)Ended earlyNCT01519427
What this trial is testing

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Who this might be right for
Recurrent MelanomaStage IIIA MelanomaStage IIIB Melanoma+2 more
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Study completedNCT02296996
What this trial is testing

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Who this might be right for
Malignant Melanoma
Universitair Ziekenhuis Brussel 25
Testing effectiveness (Phase 2)UnknownNCT03754179
What this trial is testing

Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma

Who this might be right for
Melanoma
Universitair Ziekenhuis Brussel 63
Testing effectiveness (Phase 2)Ended earlyNCT03580382
What this trial is testing

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Who this might be right for
Melanoma
NYU Langone Health 3
Large-scale testing (Phase 3)Study completedNCT01227889
What this trial is testing

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Who this might be right for
Cancer
GlaxoSmithKline 251
Early research (Phase 1)Study completedNCT01787500
What this trial is testing

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Who this might be right for
BRAF NP_004324.2:p.V600XKRAS wt AlleleMetastatic Malignant Solid Neoplasm+4 more
M.D. Anderson Cancer Center 47
Very early researchActive Not RecruitingNCT03543969
What this trial is testing

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Who this might be right for
Melanoma (Skin)Skin CancerSkin Melanoma+1 more
H. Lee Moffitt Cancer Center and Research Institute 14
Testing effectiveness (Phase 2)WithdrawnNCT02109653
What this trial is testing

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer